Skip to main content
Equibles

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in RXRX — Recursion Pharmaceuticals, Inc.

CIK 861177 NEW YORK, NY
Back to RXRX Full portfolio

Position in RXRX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$2,789,668
-$9,562,159 QoQ
Shares Held
760,129
-81.1% QoQ
Ownership
0.142%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#41
of 344 holders
Holding Since
Dec 2021
19 quarters on record
Voting authority Sole 42% Shared 0% None 58%

Common Shares in RXRX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,443,898,601 across 206 Biotechnology names. RXRX ranks #90 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 3,086,683 $1,533,248,041
2 REGN
Regeneron Pharmaceuticals, Inc.
 716,560 $446,803,817
3 ALNY
Alnylam Pharmaceuticals, Inc.
 727,848 $219,104,078
4 INCY
Incyte Corp
 1,508,720 $171,028,494
5 RVMD
Revolution Medicines, Inc.
 912,335 $170,862,094
6 INSM
INSMED Inc
 1,335,071 $142,345,265
7 IONS
Ionis Pharmaceuticals Inc
 1,454,672 $115,340,938
8 MRNA
Moderna, Inc.
 1,521,849 $106,575,080

All Filings in RXRX

Export CSV
19 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,789,668 760,129
2026-03-31 $12,351,827 4,023,398
2025-12-31 $16,667,641 4,075,219
2025-09-30 $20,481,249 4,196,978
2025-06-30 $23,354,506 4,615,516
2025-03-31 $33,901,087 6,408,524
2024-12-31 $15,272,040 2,259,178
2024-09-30 $14,107,538 2,140,750
2024-06-30 $15,732,539 2,097,672
2024-03-31 $2,051,515 205,769
2023-12-31 $2,236,965 226,873
2023-09-30 $1,618,554 211,576
2023-06-30 $861,124 115,278
2023-03-31 $768,902 115,278
2022-12-31 $824,437 106,931
2022-09-30 $817,991 76,879
2022-06-30 $418,827 51,453
2022-03-31 $345,068 48,194
2021-12-31 $607,309 35,453